Establishment and validation of a survival prediction model for stage IV non-small cell lung cancer: a real-world study
A clinical predictive model was developed to predict 3-year survival in patients with advanced non-small cell lung cancer. The study demonstrated that chemotherapy combined with immunotherapy is superior to chemotherapy alone.
Authors
- Junyan Zhang
- Jing Zeng (ORCID: https://orcid.org/0000-0002-4736-4210)
- Feng Li (ORCID: https://orcid.org/0000-0001-5886-6382)
- Fangyu Li (ORCID: https://orcid.org/0000-0003-2340-3622)
- Xu Tingting (ORCID: https://orcid.org/0009-0005-5742-3682)
- Zhiying Hao
- Yimeng Guo
- Keao Zheng
Institutions
- Shanxi Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-06
- DOI
- https://doi.org/10.3389/fimmu.2025.1508721
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52